<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.4)*
IDEC PHARMACEUTICALS CORPORATION
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, No Par Value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
004493701
- --------------------------------------------------------------------------------
(CUSIP Number)
Donald F. Parman, SmithKline Beecham Corporation
One Franklin Plaza, Philadelphia, PA 19102
Telephone 215-751-7633
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
March 7, 1997
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
SCHEDULE 13D
CUSIP NO. 857304100 PAGE 2 OF 6 PAGES
- --------------------------------------------------------------------------------
This Amendment No. 4 amends and supplements the Statement on Schedule 13D
manually filed with the Securities and Exchange Commission (the "Commission") on
April 24, 1995 (the "Initial Statement") filed jointly by SmithKline Beecham
plc, SmithKline Beecham Corporation, and S.R. One, Limited; Amendment No. 1
electronically filed on September 26, 1996; Amendment No. 2 electronically filed
on December 13, 1996; and Amendment No. 3 electronically filed on March 3, 1997
with respect to ownership of securities of IDEC Pharmaceuticals Corporation.
The undersigned hereby amends and supplements Item 5 of the Initial Statement by
the following information (capitalized terms used herein without definition
shall have the same meaning as set forth in the Initial Statement.) Since the
reporting person now holds less than 5% with this filing, further reporting
under Schedule 13-D is no longer required.
<PAGE> 3
SCHEDULE 13D
CUSIP NO. 0004493701 Page 2 of 5 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SmithKline Beecham Corporation
23-1099050
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Pennsylvania
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES 638,360
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING None
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
638,360
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
None
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
638,360
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
3.5%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
<PAGE> 4
Page 3 of 5 Pages
Item 1. Security and Issuer.
Item 2. Identity and Background.
Item 3. Source and Amount of Funds or Other Consideration.
Item 4. Purpose of Transaction.
<PAGE> 5
Page 4 of 5 Pages
Item 5. Interest in Securities of the Issuer.
(a) Amount and Percent Beneficially Owned
<TABLE>
<CAPTION>
Registered Name No. of Shares Percent
<S> <C> <C>
SmithKline Beecham Corporation 638,360 3.5%
</TABLE>
(b)
(c) The reporting persons sold 467,500 shares of Common Stock
in the open market in the following manner:
<TABLE>
<CAPTION>
Registered Name Transaction Date Number of Share Price Per Share
<S> <C> <C> <C>
SmithKline Beecham Corporation March 4, 1997 30,000 24.50
SmithKline Beecham Corporation March 5, 1997 15,000 24.50
SmithKline Beecham Corporation March 6, 1997 12,500 24.50
SmithKline Beecham Corporation March 6, 1997 7,500 24.625
SmithKline Beecham Corporation March 7, 1997 40,000 24.875
SmithKline Beecham Corporation March 7, 1997 40,000 25.00
SmithKline Beecham Corporation March 7, 1997 10,000 25.25
SmithKline Beecham Corporation March 7, 1997 10,000 25.375
SmithKline Beecham Corporation March 7, 1997 25,000 25.50
SmithKline Beecham Corporation March 7, 1997 12,500 25,625
SmithKline Beecham Corporation March 7, 1997 5,000 25.75
SmithKline Beecham Corporation March 7, 1997 45,000 25.875
SmithKline Beecham Corporation March 10, 1997 12,500 26.125
SmithKline Beecham Corporation March 11, 1997 165,000 29.50
SmithKline Beecham Corporation March 11, 1997 10,000 29.625
SmithKline Beecham Corporation March 11, 1997 25,000 30.00
SmithKline Beecham Corporation March 14, 1997 2,500 28.50
------------
467,500
</TABLE>
(d)
(e)
Item 6. Contracts, Arrangements, Understandings or
Relationship With respect to Securities of the Issuer.
Item 7. Materials to be Filed as Exhibits.
<PAGE> 6
Page 5 of 5 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, the undersigned certifies that the information set forth in the
Statement is true, correct and complete.
SMITHKLINE BEECHAM CORPORATION
By: /s/Donald F. Parman
------------------------------
Donald F. Parman
Secretary
DATED: March 17, 1997
